8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

September 5, 2023
Date of Report (Date of earliest event reported)

AptarGroup, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation) 1-11846
(Commission File Number) 36-3853103
(IRS Employer Identification No.)

265 Exchange Drive, Suite 301, Crystal Lake, Illinois 60014

(Address of principal executive offices)

Registrant’s telephone number, including area code: 815-477-0424

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $.01 par value	ATR	New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company               ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.       ¨

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 5, 2023, the Board of Directors (the “Board”) of AptarGroup, Inc. (the “Company”) appointed Sarah Glickman as a director effective as of such date. Ms. Glickman will serve as a director for a term expiring at the Company’s 2024 annual meeting of stockholders. The Board (i) determined that Ms. Glickman qualifies (a) as an “independent director” pursuant to the rules of the New York Stock Exchange, and (b) as an “audit committee financial expert” pursuant to the rules of the U.S. Securities and Exchange Commission (the “SEC”); and (ii) has appointed Ms. Glickman as a member of the Audit Committee of the Board.

Ms. Glickman, 54, currently serves as the Chief Financial Officer and Principal Accounting Officer of Criteo S.A., a global commerce media company. Prior to joining Criteo, Ms. Glickman was the Acting Chief Financial Officer at XPO, Inc., a leading global provider of transportation and logistics solutions, where she previously served as Senior Vice President, Corporate Finance and Transformation. Before that, she held global executive roles at Novartis and Honeywell International, and served in various executive roles in shared services and operations, internal audit, transformation and controllership at both Honeywell International and Bristol-Myers Squibb. She started her career at PricewaterhouseCoopers. Ms. Glickman is a U.S. CPA and a U.K. Fellow Chartered Accountant with a degree in economics from the University of York in England. Since 2021, Ms. Glickman has served on the Board of Directors and is Chair of the Audit Committee for 2seventy bio, Inc., a biotech company (previously part of bluebird bio, Inc.).

Ms. Glickman’s compensation for service on the Board will be consistent with that of other non-employee directors of the Company, as described in the Company’s definitive proxy statement with respect to its 2023 annual meeting of stockholders filed with the SEC on March 24, 2023. There are no other arrangements or understandings between Ms. Glickman and any other person pursuant to which she was appointed as director, and Ms. Glickman is not a party to any transaction with the Company that would require disclosure under Item 404(a) of Regulation S-K. 

Item 7.01. Regulation FD Disclosure.

On September 5, 2023, the Company issued a press release announcing Ms. Glickman’s appointment to the Board. A copy of the press release is furnished as Exhibit 99.1 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1	Press release issued by AptarGroup, Inc. dated September 5, 2023.
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	AptarGroup, Inc.
Date:  September 5, 2023	By:	/s/ Kimberly Y. Chainey
		Kimberly Y. Chainey
		Executive Vice President, Chief Legal Officer and Corporate Secretary

EX-99.1

Exhibit 99.1

Aptar Appoints Global Finance and Operations Veteran

Sarah Glickman to its Board of Directors

Crystal Lake, Illinois, September 5, 2023 -- AptarGroup, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, today announced that Sarah Glickman, an accomplished leader with more than 30 years of global financial and operational experience, has joined its Board of Directors.

“We are pleased to welcome Sarah Glickman to our Board of Directors. Sarah’s extensive knowledge of all aspects of corporate finance coupled with her global operational experience, including in the pharmaceutical industry for companies like Novartis and Bristol-Myers Squibb, makes her an important addition to Aptar’s Board of Directors,” said Stephan B. Tanda, Aptar President and CEO.

Sarah currently serves as the Chief Financial Officer and Principal Accounting Officer for Criteo S.A., a global commerce media company. Prior to joining Criteo, Sarah was the Acting Chief Financial Officer at XPO, Inc. She also held global executive roles at Novartis and Honeywell International and started her career at PricewaterhouseCoopers. Since 2021, Sarah has served on the Board of Directors and is Chair of the Audit Committee for 2seventy bio, Inc., a biotech company (previously part of bluebird bio, Inc.).   Candace Matthews, Chairperson of Aptar’s Board of Directors, stated, “We are excited to welcome Sarah to Aptar’s Board of Directors. Her strong operational and financial leadership roles in large and complex global companies, such as Honeywell International, will benefit Aptar and its shareholders. Sarah’s appointment also underscores Aptar’s commitment to a demographically and culturally diverse board; with her appointment five out of the ten directors are women.”
Sarah Glickman Joins Aptar’s Board of Directors

On her appointment, Sarah Glickman said, “I am thrilled to join Aptar’s Board of Directors. I look forward to leveraging my experience and perspective to help the company continue to grow and increase shareholder value while staying true to Aptar’s purpose of transforming ideas into solutions that improve everyday life.”

Glickman is a U.S. CPA and a U.K. Fellow Chartered Accountant with a degree in economics from the University of York, England. 

About Aptar

Aptar is a global leader in drug and consumer product dosing, dispensing and protection technologies. Aptar’s innovative solutions and services serve a variety of end markets including pharmaceutical, beauty, personal care, home care, food and beverage. Using insights, proprietary design, engineering and science to create dispensing, dosing and protective technologies for many of the world’s leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has 13,500 dedicated employees in 20 countries. For more information, visit www.aptar.com.

# # #

1

Investor Relations Contact:	Media Contact:
Mary Skafidas	Katie Reardon
mary.skafidas@aptar.com	katie.reardon@aptar.com
347-351-6407	815-479-5671

2

XML

Cover	Sep. 05, 2023
Cover [Abstract]
Document Type	8-K
Amendment Flag	false
Document Period End Date	Sep. 05, 2023
Entity File Number	1-11846
Entity Registrant Name	AptarGroup, Inc.
Entity Central Index Key	0000896622
Entity Tax Identification Number	36-3853103
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	265 Exchange Drive
Entity Address, Address Line Two	Suite 301
Entity Address, City or Town	Crystal Lake
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60014
City Area Code	815
Local Phone Number	477-0424
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common Stock, $.01 par value
Trading Symbol	ATR
Security Exchange Name	NYSE
Entity Emerging Growth Company	false